Avacta is seeking to capitalise on the positive perception shift in the diagnostic market since COVID-19 brought testing to the masses. An M&A-led growth strategy, complemented by internal capabilities, notably the proprietary Affimer platform, should create a self-sustaining Diagnostics business. The acquisition of Launch Diagnostics was the first step, with additional complementary targets being sought and the firepower to execute. Meanwhile in Therapeutics, lead asset AVA6000 continues to pro ....
13 Dec 2022
Avacta: Diagnostics business back into the spotlight
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Avacta: Diagnostics business back into the spotlight
Avacta Group PLC (AVCT:LON), 45.2 | Avacta Group PLC (AVCT:LON), 45.2
- Published:
13 Dec 2022 -
Author:
Franc Gregori | Lala Gregorek | Philippa Gardner -
Pages:
18
Avacta is seeking to capitalise on the positive perception shift in the diagnostic market since COVID-19 brought testing to the masses. An M&A-led growth strategy, complemented by internal capabilities, notably the proprietary Affimer platform, should create a self-sustaining Diagnostics business. The acquisition of Launch Diagnostics was the first step, with additional complementary targets being sought and the firepower to execute. Meanwhile in Therapeutics, lead asset AVA6000 continues to pro ....